Johns Hopkins abstract accepted for presentation at USCAP


In March 2016, researchers from the Johns Hopkins Hospital will present results of a study examining the clinical utility of Sienna’s Anti-hTERT antibody (SCD-A7).

The study, led by Associate Director of Cytopathology at Johns Hopkins, Assistant Professor Christopher VandenBussche, M.D., Ph.D., used Sienna’s reagent to detect the presence of telomerase, in combination with traditional urine cytomorphology, for the assessment of urothelial neoplasm in urinary tract cytopathology specimens. 

Results showed improved positive predictive value for both high grade and low grade urothelial carcinoma when compared with cytomorphology alone, whilst maintaining excellent specificity.

The findings will be presented in detail at the 2016 Annual Meeting of the United States and Canadian Academy of Pathology

Sienna’s COO, Matthew Hoskin said “We believe the detection of telomerase in epithelial cells from a range of specimen types will add useful diagnostic information to assist pathologists in the assessment of cancer. We are thrilled to have Johns Hopkins Hospital, a world renowned institution, presenting data to demonstrate the clinical utility of our telomerase detection technology.”


No Very

Captcha Image

Sign up for updates